Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-02
2007-10-02
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S359000, C514S367000, C514S416000, C514S438000, C514S443000, C514S466000, C514S649000, C546S114000, C548S152000, C548S257000, C548S506000, C549S049000, C549S074000, C549S434000, C564S306000
Reexamination Certificate
active
10704329
ABSTRACT:
Substituted cyclohexane-1,4-diamine compounds, methods for production thereof, pharmaceutical compositions comprising these compounds and methods of treatment using these compounds.
REFERENCES:
patent: 4113866 (1978-09-01), Lednicer
patent: 4447454 (1984-05-01), Lednicer
patent: 5153226 (1992-10-01), Chucholowski et al.
patent: 5200408 (1993-04-01), Bru-Magniez et al.
patent: 5565568 (1996-10-01), Cho et al.
patent: 5773441 (1998-06-01), Hipskind et al.
patent: 6194437 (2001-02-01), Horwell et al.
patent: 6307017 (2001-10-01), Coy et al.
patent: 6849622 (2005-02-01), Yasuda et al.
patent: 7138397 (2006-11-01), Yasuda et al.
patent: 2002/0028799 (2002-03-01), Naylor et al.
patent: 2002/0055759 (2002-05-01), Shibuya
patent: 2002/0169101 (2002-11-01), Gonzalez et al.
patent: 2002/0177689 (2002-11-01), Benson et al.
patent: 2003/0119714 (2003-06-01), Naylor et al.
patent: 2004/0023862 (2004-02-01), Smart et al.
patent: 2004/0087561 (2004-05-01), Gonzalez et al.
patent: 2004/0110768 (2004-06-01), Higginbottom et al.
patent: 2004/0116440 (2004-06-01), Higginbottom et al.
patent: 0 380 063 (1990-03-01), None
patent: 0 415 413 (1991-03-01), None
patent: WO95/00542 (1995-01-01), None
patent: WO96/31214 (1996-10-01), None
patent: WO97/06803 (1997-02-01), None
patent: WO98/07718 (1998-02-01), None
patent: WO 01/68120 (2001-09-01), None
patent: WO 02/30890 (2002-04-01), None
patent: WO 02/30891 (2002-04-01), None
patent: WO 02/40008 (2002-05-01), None
patent: WO 02/40022 (2002-05-01), None
patent: WO 02/40069 (2002-05-01), None
patent: WO 02/40468 (2002-05-01), None
patent: WO 02/40469 (2002-05-01), None
patent: WO 02/40475 (2002-05-01), None
Crawford et al, “Steroid Injection for Heel Pain: Evidence of Short-Term Effectiveness. A Randomized Controlled Trial,” Rheumatology, vol. 38, p. 974-977 (1999).
Richard J. Lewis, Sr., Hawley's Condensed Chemical Dictionary (14thEd.) (2001).
Lednicer, STN International, HCAPLUS Database, Columbus, OH, Accession No. 1979:86991, Reg. Nos. 68967-88-4 and 68967-89-5.
James M. Wu, et al., “Discovery of High Affinity Bombesin Receptor Subtype 3 Agonists”, Molecular Pharmacology, (1996) pp. 1355-1363, vol. 50, The American Society for Pharmacology and Experimental Therapeutics.
Kazuyuki Yamada, et al., “Hyperrsponsiveness to Platable and Aversive Taste Stimuli in Genetically Obese (Bonbesin Receptor Subtype-3-Deficient) Mice”, Physiology & behavior, (1999), pp. 863-867, vol. 66, No. 5, the Elsevier Science Inc., PII S0031-9384(99)00032-3.
Zahra Fathi, et al., “BRS-3: A Novel Bombesin Receptor Subtype Selectively Expressed in Testis and Lung Carcinoma Cells”, The Journal of Biological Chemistry, (1993), pp. 5979-5984, vol. 268, No. 8.
Valentin Gorbulev, et al., “Molecular Cloning of a New Bombesin Receptor Subtype Expressed in Uterus During Pregnancy”, Eur. J. Biochem., (1992), pp. 405-410, vol. 208.
Antonello Mai, et al., “5-Alkyl-2-(Alkylthlo)-6-(2,6-Dihalophenylmethyl)-3,4-Dihydropyrimidin-4(3H)-C Novel Potent and Selective Dihydro-Alkoxy-Benzyl-Oxoprimdine Derivative”, J. Med. Chem., (1999), pp. 619-627, vol. 42, The American Chemical Society.
Christopher J. Moody, et al., “Diels-Alder Reactively of Pyrano [4,3-b]Indol-3-Ones, Indole 2,3-Quinodimethane Analogues”, J. Chem. Soc. Perkin Trans., (1990), pp. 673-679.
Dirk Webber, et al., “Systematic Optimization of a Lead-Structure Identities for a Selective Short Peptide Agonist for the Human Orphan Receptor BRS-3”, Journal of Peptide Science, (2002), pp. 461-475, vol. 8, Wiley Interscience.
Samuel A. Mantey, et al., “Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates that it has a Unique Pharmacology Compared with the Other Mammalian Bombesin Receptors”, The Journal of Biological Chemistry, (1997), pp. 26062-26071, vol. 272, No. 41.
Tapas K. Pradhan, et al., “Identification of a Unique Ligand Which had High Affinity for all Four Bombesin Receptor Subtypes”, European Journal of Pharmacology, (1998), pp. 275-287, vol. 343.
K Yamada, et al., “Role of Bombesin (BN)-Like Peptides/Receptors in Emotional Behavior by Comparison of Three Strains of BN-Like Peptide Receptor knockout Mice”, Molecular Psychiatry, (2002), pp. 113-117, vol. 7, Nature Publishing Group.
A. Floersheimer, et al., “Solid-Phase Synthesis of Peptides with the Highly Acid-Sensitive HMPB Linker”, Peptides, (1990), pp. 131-132, ESCOM Science Publishers B.V.
Kazuyuki Yamada, et al., “Differential Effects of Social Isolation Upon Body Weight, Food Consumption, and Responsiveness to Novel and Social Environment in Bombesin Receptor Subtype-3 (BRS-3) Dedicient Mice”, Physiology & Behavior, (2000), pp. 555-561, vol. 68.
Dirk Weber, et al., “Design of Selective Peptidomimetic Agonists for the Human Orphan Receptor BRS-3”, Journal of Medicinal Chemistry, (2003), pp. 1919-1930, vol. 46, No. 10, The American Chemical Society.
Baodong Sun, et al., “Presence of Receptors for Bombesin/Gastrin-Releasing Peptide and mRNA for Three Receptor Subtypes in Human Prostate Cancers”, The Prostate, (2000), pp. 295-303, vol. 42, Wiley-Liss Inc.
Hiroko Ohki-Hamzaki, et al., “Mice lacking Bombesin Receptor Subtype-3 Develop Metalbolic Defects and Obesity”, Letters to Nature, (Nov. 1997), pp. 165-169, vol. 390.
Samuel A. Mantey, et al., Rational Design of a Peptide Agonist That Interacts Selectively with the Orphan Receptor, Bombesin Receptor Subtyoe 3*:, Selective BRS-3 Ligand, (2000), pp. 9219-9228).
Achim Fleischmann, et al., “Bombesin Receptors in Distant Tissue Compartments of Human Pancreatic Diseases”, Laboratory Investigation, (2000), pp. 1807-1817, vol. 80, No. 12, The United States and Canadian Academy of Pathology, Inc.
Barber Doerner, et al., “Preparation of Carboxy-Modified Peptide Fragments Using Alkyoxybenzaldehyde Resins”, Peptides, (1998), pp. 90-91.
Valetin Gorbulev, et al., “Organization and Chromosomal Localization of the Gene for the Human Bombesin Receptor Subtype Expressed in Pregnant Uterus”, FEBS Letters, (1994), pp. 260-264, vol. 340, Federation of European Biochemical Societies.
Baodong Sun, et al., “The Presence of Receptors for Bombesin/GRP and mRNA for Three Receptor Subtypes in Human Ovarian Epithellal Cancers”, Regulatory Peptides, (2000), pp. 77-84, vol. 90, Elsevier Science B.V.
Ali Ardati, et al., “Interaction of [3H] Orphanin FQ and125I-Tyr14-Orphanin FQ with the Orphanin FQ Receptor: Kinetics and Modulation by Cations and Guanine Nucleotides”, Molecular Pharmacy, (1997), pp. 816-824, vol. 51, The American Society for Pharmacology and Experimental Therapeutics (1997), pp. 816-824, vol. 51, The American Society for Pharmacology and Experimental Therapeutics.
Fuad A. Abdulla, et al., “Axotomy Reduces the Effect of Analgesic Opioids yet Increases the Effect of Nociceptin on Dorsal Root Ganglion Neurons”, The Journal of Neuroscience, (Dec. 1, 1998), pp. 9685-9694, vol. 18.
Girolamo Calo, et al., “Pharmacology of Nociceptin and its Receptor: A Novel Therapeutic Target”, British Journal of Pharmacology, (2000), pp. 1261-1283, vol. 129, Mcmillan Publishers Ltd.
Hunter C. Champion, et al., “[Tyr1]-Nociceptin, a Novel Nociceptin Analog, Decreases Systemic Arterial Pressure by a Naloxone-Insensitive Mechanism In the Rat”, Biochemical and Biophysical Research Communications, (1997), pp. 309-312, vol. 234, The Academic Press.
Mark Conner, et al., “The Effect of Nociceptin on Ca2+Channel Current and Intracellular Ca2+In the SH-SY5Y Human Neuroblastoma Cell Line”, British Journal of Pharmacology, (1996), pp. 205-207, vol. 118, Stockton Press.
Tristan Darland, et al., “Orphanin FQ/Nociceptin: a Role in Pain and Analgesia, But so Much More”, Extracellular Space, (1998), pp. 215-221, vol. 21, No. 5, Elsevier Science Lt
Englberger Werner
Hennies Hagen-Heinrich
Koegel Babette-Yvonne
Sundermann Bernd
Anderson Rebecca
Crowell & Moring LLP
Freistein Andrew B.
Gruenenthal GmbH
LandOfFree
Substituted cyclohexane-1,4-diamine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted cyclohexane-1,4-diamine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted cyclohexane-1,4-diamine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3893954